Filing Analysis
Spectral AI held its 2026 Annual Meeting on May 29, 2026, where stockholders elected the Board of Directors and ratified the appointment of Forvis Mazars LLP as auditors. Most significantly, stockholders approved the issuance of common stock to Hudson Bay Master Fund Ltd. pursuant to a Securities Purchase Agreement dated October 24, 2025.
🚩 Red Flags
- The approval of shares for Hudson Bay Master Fund Ltd. suggests potential dilution of existing shareholders, a common risk for micro-cap companies relying on institutional funding.
📋 Key Facts
- Annual Meeting held May 29, 2026, with 54.30% of eligible shares represented (17,267,570 of 31,823,985 shares).
- Re-elected Board members: J. Michael DiMaio, Richard Cotton, Martin Mellish, Deepak Sadagopan, and Marion Snyder.
- Ratified Forvis Mazars LLP as the independent registered public accounting firm for fiscal year 2026.
- Approved the 'Hudson Bay Proposal' to reserve and issue shares to Hudson Bay Master Fund Ltd. per a Securities Purchase Agreement dated October 24, 2025, in compliance with Nasdaq Rule 5635(d).
Spectral AI, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted De Novo Classification for its DeepView® System. This authorization allows the company to immediately commence commercial distribution activities for the system in the United States.
📋 Key Facts
- On May 26, 2026, Spectral AI received FDA De Novo Classification for its DeepView® System.
- The classification authorizes the company to begin commercial distribution of the system in the U.S.
- The announcement was disclosed under Item 7.01 (Regulation FD Disclosure) with an accompanying press release as Exhibit 99.1.
Spectral AI, Inc. formalized an employment agreement with CEO Vincent S. Capone, establishing a $500,000 base salary and a significant equity grant. The agreement includes a guaranteed minimum bonus and retroactive vesting for a portion of the equity.
🚩 Red Flags
- Guaranteed minimum bonus of $250,000 regardless of performance milestones.
- Retroactive vesting of 100,000 RSUs to April 1, 2026, which is prior to the agreement execution date of April 17, 2026.
📋 Key Facts
- Annual base salary set at $500,000 effective April 17, 2026.
- Eligible for an annual target bonus of up to 100% of base salary, with a guaranteed minimum floor of $250,000.
- Granted 200,000 restricted stock units (RSUs) under the 2023 Long Term Incentive Plan.
- 50% of RSUs (100,000 shares) vested retroactively on April 1, 2026.
- Remaining 50% of RSUs will vest on April 1, 2027, with full acceleration upon a change of control.
Spectral AI, Inc. has appointed David McGuire as its new Chief Financial Officer, effective May 4, 2026. Mr. McGuire brings over 20 years of experience from roles at Solo Brands, EZCORP, and Ernst & Young, and will receive a $330,000 base salary plus equity incentives.
📋 Key Facts
- David McGuire appointed as CFO effective May 4, 2026
- Annual base compensation set at $330,000 with a target bonus of up to 30%
- Granted 150,000 stock options under the 2023 Long Term Incentive Plan, vesting over three years
- McGuire previously served as Chief Accounting Officer at Solo Brands, Inc. and Deputy CFO at EZCORP, Inc.
- McGuire's background includes 14 years at Ernst & Young LLP and experience in material weakness remediation
Spectral AI, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release and details regarding a conference call held on March 24, 2026, to discuss these results.
📋 Key Facts
- Reported financial results for the quarter and year ended December 31, 2025.
- Hosted a conference call on March 24, 2026, at 5:00 pm Eastern Time.
- The company is classified as an emerging growth company.
- Securities are traded on The Nasdaq Stock Market LLC under symbols MDAI and MDAIW.
Spectral AI announced a $31.7 million funding award from the Biomedical Advanced Research and Development Authority (BARDA). The capital is intended to accelerate the development of additional features for the Company's DeepView® System, an AI-driven burn wound technology.
📋 Key Facts
- Awarded $31.7 million in funding from BARDA on March 18, 2026.
- Funding is specifically for the DeepView® System, an AI-driven burn wound assessment tool.
- The award supports the acceleration of additional feature aspects for the technology.
- The announcement was made via a press release furnished as Exhibit 99.1.